Founded in Madrid, the company is a spin-off of the Visual Optics and Biophotonics Lab at Spanish Research Institute CSIC.
The team at 2eyesVision has developed the SimVis, a medical device that allows the simulation of different kinds of intraocular or contact lenses for the visual corrections of patients affected by presbyopia or cataracts.
The SimVis is a see-through device that simulates how a patient will see before surgery. This is of great help both for the clinician, that has to recommend a specific lens, and for the patient, who reduces uncertainty and potential post-surgery rejections.
For those patients to be treated with contact lenses, the device reduces the trial and error phase until the patient moves ahead with a specific lens.
Bullnet Capital invested in 2eyesVision in June of 2017 and has continued supporting the project ever since.